Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022

Description: “Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.

The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient's personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual's necessities, high efficacy and safety, concept of cancer vaccine was formulated.

The best part with cancer vaccines is that they are capable of inducing “memory effect” in the immune cells. As a result, even in the absence of cancer vaccine molecule in the body, immune cells maintain their ability to search and destroy cancer cells. These memory effects are engraved on lymphocytes which keep on producing antigen long after the introduction of the initiator molecule. Pharmaceuticals companies are investing heavily in R&D segment to discover more properties of cancer vaccines. The benefits offered by cancer vaccine have posed the market to increase several folds.

At present the breast cancer vaccines are in emerging stages and this market has yet to be tapped by pharmaceutical companies. They are diverging funds towards research and development segment for advances in innovative breast cancer vaccines which will generate large amount of revenues. In recent years significant progress has been made on technological and scientific levels but still no vaccine for the treatment of breast cancer has seen market introduction in any part of the globe.

The present therapeutics available in market for breast cancer shows modest results in majority of patients which offers unexplored marketing opportunities for better innovative products to enter in competition. It is expected that more oncologists will prescribe the innovative breast cancer vaccines to their patients due to greater therapeutic effects. The higher rates of prescription would lead to high degree of market penetration and increased market share. The revenues generated in this way will encourage the pharmaceutical companies to fund new projects for the development of better breast cancer vaccines.

The first commercially available breast cancer vaccine is expected to be available in the market in next 5-7 years. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the advance stages of clinical trials which are supposed to clear the targeted end points. Market introduction of these new products are supposed to generate significant revenues for the pharmaceutical companies in coming years.

Contents:

1. What are Cancer Vaccines?
2. Mechanism of Cancer Vaccines
   2.1 Idiotype Cancer Vaccine Mechanism
   2.2 Cellular Cancer Vaccines Mechanism
   2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
   2.4 Peptide Cancer Vaccine Mechanism
   2.5 Tumor Host Interaction Cancer Vaccine Mechanism
3. Mechanism of Breast Cancer Vaccine
   3.1 Principle Strategies for Eliciting Immune System
      3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity & Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

4. Global Breast Cancer Incidence
   4.1 US
   4.2 Europe
   4.3 Asia
   4.4 Rest of the World

5. Global Breast Cancer Vaccine Market Current Scenario
   5.1 Unexplored Opportunity
   5.2 Global Breast Cancer Vaccine Pipeline Overview

6. Need for Personalized Breast Cancer Vaccines

7. Global Breast Cancer Vaccine Market Dynamics
   7.1 Favorable Parameters
   7.2 Commercialization Challenges


9. FDA Guideline for the Development & Marketing of Cancer Vaccines
   9.1 Considerations for Both Early and Late Phase Clinical Trials
      9.1.1 Patient Population
      9.1.2 Monitoring The Immune Response
      9.1.3 Biomarkers As Evidence Of Efficacy
      9.1.4 Adjuvants Used To Stimulate Immune Response
      9.1.5 Multi-Antigen Vaccines
      9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
      9.1.7 Concomitant And Subsequent Therapies
      9.2 Considerations for Early Phase Clinical Trials
         9.2.1 Starting Dose And Dosing Schedule
         9.2.2 Booster And Maintenance Therapy
         9.2.3 Dose Escalation
         9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
      9.3 Considerations For Late Phase Clinical Trials
         9.3.1 Safety Profile From Early Phase Clinical Trials
         9.3.2 Endpoints
         9.3.3 Statistical Issues
         9.3.4 Control Issues
         9.3.5 Delayed Vaccine Effect
         9.3.6 Autologous Vaccine Trials
         9.3.7 Accelerated Approval Regulations

10. Global Breast Cancer Vaccine Clinical Pipeline by Company & Phase
    10.1 Preclinical
    10.2 Phase-I
    10.3 Phase-I/II
    10.4 Phase-II
    10.5 Phase-II/III
    10.6 Phase-III

11. Discontinued & Suspended Breast Cancer Vaccine in Clinical Pipeline by Company & Phase
    11.1 Suspended
    11.2 No Development Reported
    11.3 Discontinued

12. Competitive Landscape
    12.1 Advaxis
    12.2 AlphaVax
    12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

List of Figures:
Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Development of a Cellular Immune Response against TAA
Figure 4-1: US –Number of New Cases & Deaths of Breast Cancer, 2016
Figure 5-1: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-2: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 5-3: Global Breast Cancer Vaccine Pipeline by Phase (%), 2016 till 2022
Figure 5-4: Global Breast Cancer Vaccine Pipeline by Phase (Numbers), 2016 till 2022
Figure 6-1: Overview of Personalized Cancer Vaccines Development
Figure 6-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 6-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 7-1: Favorable Parameters for Breast Cancer Vaccine Development
Figure 7-2: Challenges for Breast Cancer Vaccine Market
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: AlphaVax Clinical Pipeline Overview
Figure 12-3: Galena Biopharma Clinical Pipeline Overview
Figure 12-4: Generex Biotechnology Clinical Pipeline Overview
Figure 12-5: Immune Design Clinical Pipeline Overview
Figure 12-6: Imugene Clinical Pipeline Overview
Figure 12-7: Immunovaccine Clinical Pipeline Overview
Figure 12-8: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-9: NewLink Genetics Corporation Clinical Pipeline
Figure 12-10: TapImmune Clinical Pipeline Overview
Figure 12-11: ViroMed Clinical Pipeline Overview

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3989513/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Breast Cancer Vaccine Market & Clinical Pipeline Outlook 2022
Web Address: http://www.researchandmarkets.com/reports/3989513/
Office Code: SC2GBNJY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>CD-ROM - Single User</td>
<td>USD 2500 + USD 56 Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 3000 + USD 56 Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp